4.70Open4.70Pre Close0 Volume1.40K Open Interest6.00Strike Price0.00Turnover233.89%IV2.29%PremiumJan 17, 2025Expiry Date4.46Intrinsic Value100Multiplier21DDays to Expiry0.24Extrinsic Value100Contract SizeAmericanOptions Type0.8977Delta0.0301Gamma2.16Leverage Ratio-0.0253Theta0.0027Rho1.94Eff Leverage0.0045Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet